Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 38, Issue 3, 2002, Pages 309-315

  Sánchez, José Miguel ^a,b   Balañá, Carme ^a,b   Font, Albert ^a,b   Sánchez, José Javier ^a,b   Manzano, José Luis ^a,b   Guillot, Mónica ^a,b   Margelí, Mireia ^a,b   Richardet, Martin ^a,b   Rosell, Rafael ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Polytechnic of Madrid University   (Spain)

Author keywords

Docetaxel; Efficacy; Lung cancer; Phase II; Sequence dependent; Vinorelbine

Indexed keywords

AMINOTRANSFERASE; ANTIEMETIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; NAVELBINE; RANITIDINE; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL; TAXOID; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALLERGY; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL TYPE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRANULOCYTE; HUMAN; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MYALGIA; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PHASE 2 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036889765     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00220-9     Document Type: Article

References (25)

1. Le Chevalier T., Brisgand D., Douillard J.-Y., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. 12:1994;360-367.
2. Crawford J., O'Rourke M., Schiller J.H., et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in-patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 14:1996;2774-2784.
3. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest oncology group study. J. Clin. Oncol. 16:1998;2459-2465.
4. Monnet I., Soulie P., de Cremoux H., et al. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in-patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 19:2001;458-463.
5. Kelly K., Crowley J., Bunn P.A., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest oncology group trial. J. Clin. Oncol. 19:2001;3210-3218.
6. Roszkowski K., Pluzanska A., Krzakowski M., et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer. Lung Cancer. 27:2000;145-157.
7. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in-patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2103.
8. Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patient's fron 52 randomized clinical trials. Br. Med. J. 311:1995;899-911.
9. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 346:2002;92-98.
10. Blagosklonny M.V. Mechanisms of action of cancer chemotherapeutic agents: antimicrotubule agents. Alison M.R., The Cancer Handbook. 2002;1323-1332 Nature Publishing Group, London.
11. Chen J.-G., Horwitz S.B. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res. 62:2002;1935-1938.
12. He L., Yang C.-P.H., Horwitz S.B. Mutations in β-tubuline map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol. Cancer Ther. 1:2001;3-10.
13. Martello L.A., Shen H.-J., Verdier-Pinard P., et al. A mutation in the Kα1 isotype of α-tubulin in a taxol-resistant/dependent human lung carcinoma cell line. Proc. Am. Assoc. Cancer Res. 43:2002;789. abstract 3911.
14. Nishio K., Nakamura T., Koh Y., et al. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer. 91:2001;1494-1499.
15. Martello L.A., McDaid H.M., Regl D.L., et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin. Cancer Res. 6:2000;1978-1987.
16. Campone M., Fumoleau P., Delecroix V., et al. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Ann. Oncol. 12:2001;909-918.
17. Miller V.A., Ng K.K., Krug L.M., et al. Phase I trial of docetaxel and vinorelbine in-patients with advanced non-small-cell lung cancer. Cancer. 88:2000;1045-1050.
18. Miller V.A., Krug L.M., Ng K.K., et al. Phase II trial of docetaxel and vinorelbine in-patients with advanced non-small cell lung cancer. J. Clin. Oncol. 18:2000;1346-1350.
19. Kourousis C., Androulakis N., Kakolyris S., et al. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. Cancer. 83:1998;2083-2090.
20. Bennouna J., Monnier A., Rivière A., et al. A phase II study of docetaxel and vinorelbine combination chemotherapy in-patients with advanced non-small cell lung cancer. Eur. J. Cancer. 36:2000;1107-1112.
21. Walls J.A., O'Rourke M., Garfield D., Asmar L. First-line therapy of Taxotere and Navelbine in-patients with advanced non-small-cell lung cancer: a phase II study. Proc. Am. Soc. Clin. Oncol. 19:2000;547. abstract 2158.
22. Leu K.M., Kim K.M., Larson M., et al. Phase I/II trial of docetaxel and vinorelbine in-patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer. 34:2001;105-113.
23. Hainsworth J.D., Burris H.A. III, Billings F.T. III, et al. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in-patients with advanced nonsmall cell lung carcinoma. Cancer. 92:2001;2391-2398.
24. Clark J.I., Kancharla K., Qamar R., et al. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small-cell lung cancer. Lung Cancer. 34:2001;271-277.
25. Van Meerbeeck J.P., Smit E.F., Lianes P., et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;308a. abstract 1228.